These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 11313673

  • 1. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Endo T, Sakai T, Fujimoto K, Yamamoto S, Takashima H, Haseyama Y, Nishio M, Koizumi K, Koike T, Sawada K.
    Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
    [Abstract] [Full Text] [Related]

  • 2. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H, Cai Q, Lin T, Lin X, Liu Y, Gao Y, Peng R.
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [Abstract] [Full Text] [Related]

  • 3. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM.
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [Abstract] [Full Text] [Related]

  • 4. Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases.
    Nakagawa M, Simizu Y, Suemura M, Sato B.
    Am J Hematol; 2002 May; 70(1):60-3. PubMed ID: 11994984
    [Abstract] [Full Text] [Related]

  • 5. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
    Vassiliadis T, Garipidou V, Tziomalos K, Perifanis V, Giouleme O, Vakalopoulou S.
    Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
    [Abstract] [Full Text] [Related]

  • 6. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
    Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, Wang WS, Yen CC, Yang MH, Tzeng CH, Chen PM.
    Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
    [Abstract] [Full Text] [Related]

  • 7. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
    Ahmed A, Keeffe EB.
    Am J Gastroenterol; 1999 Jan; 94(1):249-51. PubMed ID: 9934765
    [Abstract] [Full Text] [Related]

  • 8. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masauzi N.
    Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
    [Abstract] [Full Text] [Related]

  • 9. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A.
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [Abstract] [Full Text] [Related]

  • 10. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B.
    Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
    [Abstract] [Full Text] [Related]

  • 11. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
    Kim JS, Hahn JS, Park SY, Kim Y, Park IH, Lee CK, Cheong JW, Lee ST, Min YH.
    Yonsei Med J; 2007 Feb 28; 48(1):78-89. PubMed ID: 17326249
    [Abstract] [Full Text] [Related]

  • 12. [Lamivudine for the prevention of chronic hepatitis B exacerbations during chemotherapy for non-Hodgkin's lymphoma].
    van der Eijk AA, Doorduijn JK, Janssen HL, Schalm SW, Niesters HG, de Man RA.
    Ned Tijdschr Geneeskd; 2002 Jun 15; 146(24):1140-4. PubMed ID: 12092307
    [Abstract] [Full Text] [Related]

  • 13. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
    Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ.
    Cancer; 2006 Mar 15; 106(6):1320-5. PubMed ID: 16470607
    [Abstract] [Full Text] [Related]

  • 14. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM, Huang YH, Lee PC, Lin HC, Lee SD.
    J Clin Gastroenterol; 2009 Mar 15; 43(5):496-8. PubMed ID: 19247200
    [Abstract] [Full Text] [Related]

  • 15. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
    Steinberg JL, Yeo W, Zhong S, Chan JY, Tam JS, Chan PK, Leung NW, Johnson PJ.
    J Med Virol; 2000 Mar 15; 60(3):249-55. PubMed ID: 10630955
    [Abstract] [Full Text] [Related]

  • 16. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
    Schnepf N, Sellier P, Bendenoun M, Zini JM, Sanson-le Pors MJ, Mazeron MC.
    J Clin Virol; 2007 May 15; 39(1):48-50. PubMed ID: 17368969
    [Abstract] [Full Text] [Related]

  • 17. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
    Long M, Jia W, Li S, Jin L, Wu J, Rao N, Feng H, Chen K, Deng H, Liu F, Su F, Song E.
    Breast Cancer Res Treat; 2011 Jun 15; 127(3):705-12. PubMed ID: 21445574
    [Abstract] [Full Text] [Related]

  • 18. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
    Mimura N, Tsujimura H, Ise M, Sakai C, Kojima H, Fukai K, Yokosuka O, Takagi T, Kumagai K.
    Rinsho Ketsueki; 2009 Dec 15; 50(12):1715-9. PubMed ID: 20068280
    [Abstract] [Full Text] [Related]

  • 19. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
    Sugimoto R, Enjoji M, Kotoh K, Noguchi K, Tsuruta S, Nakamuta M, Nawata H.
    Fukuoka Igaku Zasshi; 2004 Oct 15; 95(10):274-9. PubMed ID: 15678886
    [Abstract] [Full Text] [Related]

  • 20. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
    Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL, Chen PJ.
    Hepatology; 2008 Mar 15; 47(3):844-53. PubMed ID: 18302293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.